Cargando…
Measurement Reproducibility in the Early Stages of Biomarker Development
Biomarker discovery and development requires measurement reproducibility studies in addition to case-control studies. Parallel pursuit of reproducibility studies is especially important for emerging technologies such as protein biomarkers based on time-of-flight mass spectrometry, the case considere...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839328/ https://www.ncbi.nlm.nih.gov/pubmed/15665389 http://dx.doi.org/10.1155/2004/726517 |
_version_ | 1782478422954475520 |
---|---|
author | Liggett, Walter S. Barker, Peter E. Semmes, O. John Cazares, Lisa H. |
author_facet | Liggett, Walter S. Barker, Peter E. Semmes, O. John Cazares, Lisa H. |
author_sort | Liggett, Walter S. |
collection | PubMed |
description | Biomarker discovery and development requires measurement reproducibility studies in addition to case-control studies. Parallel pursuit of reproducibility studies is especially important for emerging technologies such as protein biomarkers based on time-of-flight mass spectrometry, the case considered in this paper. For parallel studies, a way to improve reproducibility prior to identification of protein species is necessary. One approach is use of functional principal components analysis (PCA) as the basis for assessing measurement reproducibility. Reproducibility studies involve repeated measurement of a reference material such as a human serum standard. Measurement in our example is by SELDI-TOF (surface-enhanced laser desorption and ionization time-of-flight) mass spectrometry. Reproducibility is defined in reference to a source of variation, which in our example is associated with a type of commercially available protein biochip. We obtained spectra for 8 spots on each 11 chips. Two spectra are generally more alike when obtained from the same chip rather than different chips. Thus, our experiment indicates potential improvements from reducing variation in chip manufacture and chip handling during measurement. Our analysis involves careful registration of the spectra and characterization of the spectral differences. As shown by our example, a metrological analysis may enhance case-control studies by guiding optimization of the measurements underlying the biomarker. |
format | Online Article Text |
id | pubmed-3839328 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-38393282013-12-17 Measurement Reproducibility in the Early Stages of Biomarker Development Liggett, Walter S. Barker, Peter E. Semmes, O. John Cazares, Lisa H. Dis Markers Other Biomarker discovery and development requires measurement reproducibility studies in addition to case-control studies. Parallel pursuit of reproducibility studies is especially important for emerging technologies such as protein biomarkers based on time-of-flight mass spectrometry, the case considered in this paper. For parallel studies, a way to improve reproducibility prior to identification of protein species is necessary. One approach is use of functional principal components analysis (PCA) as the basis for assessing measurement reproducibility. Reproducibility studies involve repeated measurement of a reference material such as a human serum standard. Measurement in our example is by SELDI-TOF (surface-enhanced laser desorption and ionization time-of-flight) mass spectrometry. Reproducibility is defined in reference to a source of variation, which in our example is associated with a type of commercially available protein biochip. We obtained spectra for 8 spots on each 11 chips. Two spectra are generally more alike when obtained from the same chip rather than different chips. Thus, our experiment indicates potential improvements from reducing variation in chip manufacture and chip handling during measurement. Our analysis involves careful registration of the spectra and characterization of the spectral differences. As shown by our example, a metrological analysis may enhance case-control studies by guiding optimization of the measurements underlying the biomarker. IOS Press 2004 2005-01-18 /pmc/articles/PMC3839328/ /pubmed/15665389 http://dx.doi.org/10.1155/2004/726517 Text en Copyright © 2004 Hindawi Publishing Corporation. |
spellingShingle | Other Liggett, Walter S. Barker, Peter E. Semmes, O. John Cazares, Lisa H. Measurement Reproducibility in the Early Stages of Biomarker Development |
title | Measurement Reproducibility in the Early Stages of Biomarker Development |
title_full | Measurement Reproducibility in the Early Stages of Biomarker Development |
title_fullStr | Measurement Reproducibility in the Early Stages of Biomarker Development |
title_full_unstemmed | Measurement Reproducibility in the Early Stages of Biomarker Development |
title_short | Measurement Reproducibility in the Early Stages of Biomarker Development |
title_sort | measurement reproducibility in the early stages of biomarker development |
topic | Other |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3839328/ https://www.ncbi.nlm.nih.gov/pubmed/15665389 http://dx.doi.org/10.1155/2004/726517 |
work_keys_str_mv | AT liggettwalters measurementreproducibilityintheearlystagesofbiomarkerdevelopment AT barkerpetere measurementreproducibilityintheearlystagesofbiomarkerdevelopment AT semmesojohn measurementreproducibilityintheearlystagesofbiomarkerdevelopment AT cazareslisah measurementreproducibilityintheearlystagesofbiomarkerdevelopment |